1.Peltola, H, Heinonen, OP, Valle, M et al. . The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331: 1397–402.
2.Cutts, FT, Markowitz, LE. Successes and failures in measles control. J Infect Dis 1994; 107: (supplement 1): S32–S41.
3.Halsey, NA. The optimal age for administering measles vaccine in developing countries In: Halsev, NA, de Quadrros, CA, ed. Recent advances in immunization, Washington DC: PAHO, 1983; 4–13.
4.Heymann, DL, Kessing, Maben G, Murphy, K, Guyer, B, Foster, SO, Measles control in Yaounde: justification of a one-dose, nine month minimum age policy in tropical Africa, Lancet 1983; ii: 1470–2.
5.Orenstein, WA, Markowitz, L, Preblud, SR, Himan, AR, Tomasi, A, Bart, KJ. Appropriate ages for measles vaccination in the United States. Develop Biol Stand 1986; 65: 13–21.
6.Anderson, RM, May, RM. Infectious diseases of humans. Oxford: Oxford University Press, 1991.
7.Fine, PEM. Herd immunity: history, theory and practice. Epidemiol Rev 1993; 15: 265–302.
8.Walsh, JA. Selective primarv health care: strategies for control of disease in the developing world. IV. Measles. Rev Infect Dis 1983; 5: 330–40.
9. EPI: Expanded Programme on Immunization, Measles immunization. Wkly Epidemiol Rec 1979; 54: 337–9.
10.McLean, AR, Anderson, RM. Measles in developing countries. Part II. The predicted impact of mass immunization. Epidemiol Infect 1988; 100: 419–42.
11.Babad, HR, Nokes, DJ, Gay, NJ, Miller, E, Morgan-Capner, P, Anderson, RM. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options. Epidemiol Infect, In press.
12.Burgess, E, Garelick, H, Mann, G, Tomkins, A, (unpublished) Prediction of optimum age for measles immunization based on pre-vaccination antibody levels.
13.Markowitz, LE, Sepulveda, J, Diaz-Ortega, JL et al. Immunization of six-month old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990; 322: 580–7.
14. Ministry of Health Kenya and World Health Orgaization. Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. Bull WHO 1977; 55:21–31.
15.Dabis, F, Waldman, RJ, Mann, GF, Commenges, D, Madzou, G, Jones, TS. Loss of maternal measles antibody during infancy in an African city. Intl J Epidemiol 1989; 18: 264–8.
16.Vaisberg, A, Alvarez, JO, Hernandez, H, Guillen, D, Chu, P, Colarossi, A. Loss of maternally acquired measles antibodies in well-nourished infants and response to measles vaccination. Peru Am J Publ Hlth 1990; 80: 736–8.
17.Black, FL et al. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 1986; 124:442–52.
18.Sato, H, Albrecht, P, Reynolds, DW, Stagno, S, Ennisr, FA. Am J Dis Child 1979: 133: 1240–3.
19.Lennon, JL, Black, FL. Maternally derived measles immunity in the era of vaccine protected mothers, J Pediatr 1986; 108: 671–6.
20.Jenks, PJ, Caul, EO, Roome, APCH. Maternally derived measles immunity in children of naturally infected and vaccinated mothers. Epidemiol Infect 1988; 101: 473–6.
21.Pabst, HF, Spady, DW, Marusky, RG et al. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Inf Dis J 1992; 11: 525–9.
22.Chui, L W-L.Marusyk, RG, Pabst, HF. Measles virus specific antibody in infants in a highly vaccinated society. J Med Virol 1991; 33: 199–204.
23. Ministries of Health of Brazil, Chile. Costa Rica, Ecuador, and the Pan American Health Organization. Seroconversion rates and measles antibody titres induced by measles vaccine in Latin American Children 6–12 months of age. Bull Pan Am Health Organization 1982; 16: 272–85.
24.Williams, BG, Dye, C. Maximum likelihood for parasitologists. Parasitol Today 1994; 10: 489–93.
25.McLean, AR, Nokes, DJ, Anderson, RM. Model-based comparisons of measles immunization strategies using high dose Edmonston–Zagreb type vaccines. Intl J Epidemiol 1991; 20: 1107–?
26. ACIP. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). M M W R 1989; 38 (S–9): 1–13.
27.Fine, PEM, Zell, ER. Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol 1994; 139: 77–90.
28.Reyes, MA, Franky de Borrero, M, Roa, J, Bergonzoli, G, Saravia, MG. Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 1987; 6: 848–51.
29.Mathias, R, Meekison, J, Arcan, T, Schechter, M. The role of secondary vaccine failures in measles outbreaks. Am J Public Health 1989; 79: 475–8.
30.Deseda-Tous, J, Cherry, JD, Spencer, MJ et al. Measles revaccination. Persistence and degree of antibody titre by type of immune response. Am J Dis Child 1978; 132: 287–90.
31.Markowitz, LE, Albrecht, P, Orenstein, WA, Lett, SM, Pugliese, TJ, Farrell, D. Persistence of measles antibody after revaccination. J Infect Dis 1992; 166: 205–8.
32.Kendall, M, Stuart, A. The advanced theory of statistics. 4th edn. vol. 2. London: Charles Griffin. 1979; 96.